Friday, September 17, 2021
Resonant Therapeutics, Inc., a biotechnology company focused on cancer therapeutic discovery based on unique insights into the tumor microenvironment, today announced that the company has advanced into the next phase of its ongoing agreement with Janssen Research and Development, LLC (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. Resonant is a resident of Johnson & Johnson Innovation -- JLABS @ TMC, a premier life science incubator program.
“We are excited that our collaboration has yielded actionable data and novel therapeutic targets,” said John K. Westwick, Ph.D., CEO of Resonant. “Our IMPACT platform, rapidly growing database, and data science capabilities have generated hundreds of novel targets and dozens of unique antibody candidates.”
Under terms of the previously announced agreement, Resonant utilized its tumor-microenvironment IMPACT platform along with cells from difficult-to-treat cancers to identify large candidate target pools. Resonant also utilized its proprietary database and data science strategies to refine and prioritize candidates to yield optimal therapeutic targets. Resonant is eligible to receive additional funding upon targets licensed as a result of the collaboration.
Dr. Westwick continued, “Resonant’s tumor-microenvironment IMPACT platform discovers, validates and prioritizes novel oncology targets and antibody therapeutics with unprecedented speed. We look forward to additional commercial partnerships that leverage these capabilities.”